Summary
Graham Cooke is NIHR Research Professor based within the Department of Infectious Disease at Imperial College and leads the Infection and AMR theme of the Biomedical Research Centre.
A major focus of his research has been to provide the scientific evidence underpinning efforts to eliminate viral hepatitis as a public health threat through investigation of disease burden, modelling, and clinical studies (PROLIFICA, STOPHCV consortia and STOPHCV-1 trial). He currently leads the SEARCH collaboration conducting strategic treatment trials for hepatitis C in Vietnam (in collaboration with OUCRU and MRC Clinical Trials Unit) and the Lancet journals commission on accelerating the elimination of viral hepatitis.
In response to COVID19, he co-ordinated the virtual COVID theme of the NIHR Biomedical Research Centre and was a member of the WHO COVID-19 treatment guidelines group. He led clinical development of the COVIDnudge diagnostic and is a PI for the REACT studies which have recruited over 3 million people to self-testing studies for COVID19.
He is active in promoting access to medicine and patient safety. Since 2015 , he has been a member of the WHO Committee on the Selection and Use of Essential Medicines, serving as Chair from 2019-23. The group is responsible for updating and maintaining the WHO Essential Medicines List (EML) and other areas of medicines use such as the AWaRe index. He was appointed to the Expert groups in HIV and hepatitis (the latter as convenor) for the Infected Blood Inquiry. He is a non-executive director and Deputy Chair of the board of the MHRA.
Funding: NIHR, Wellcome Trust, UKRI, DHSC, Médecins sans Frontières, BRC Imperial College
Follow on twitter: @grahamscooke
SELECTED PUblications
Hepatitis/HIV
(2021) Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C, Wellcome Open Research, Vol:6, Pages:93-9
Simmons B, Cooke GS, Miraldo M (2019) Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis, The Lancet Global Health, Vol:7, ISSN:2214-109X, Pages:e1189-e1196
2019) Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, The Lancet, Vol:393, ISSN:0140-6736, Pages:1319-1329
2019) Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184
2017) Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus, Nature Genetics, Vol:49, ISSN:1546-1718, Pages:666-673
2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, The Lancet, Vol:388, ISSN:0099-5355, Pages:1081-1088
COVID-19
et al (2021) Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant, Science (Nov 2:eabl9551)
2021) Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults, The Lancet Regional Health - Europe, Vol:4, ISSN:2666-7762, Pages:100098-100098
Selected Publications
Journal Articles
Flower B, Hung LM, Mccabe L, et al., 2023, Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study., Elife, Vol:12, ISSN:2050-084X, Pages:1-30
Elliott P, Haw D, Wang H, et al., 2021, Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant, Science, Vol:374, ISSN:0036-8075, Pages:1-11
Elliott J, Whitaker M, Bodinier B, et al., 2021, Predictive symptoms for COVID-19 in the community: REACT-1 study of over one million people, PLOS Medicine, Vol:18, ISSN:1549-1277, Pages:1-14